Rubicon Research IPO is a significant offering opening on October 9, 2025, and closing on October 13, 2025, with a price band of ₹461 to ₹485 per equity share. The IPO aims to raise ₹1,377.5 crore, including a fresh issue of ₹500 crore and an offer for sale of ₹877.5 crore by promoters. With a solid product portfolio and growth prospects driven by innovation and regulatory approvals, Rubicon Research IPO offers investors entry into a growing pharma segment.
₹155
₹485
₹620.00
Expert Opinions
Market sentiment for Rubicon Research IPO is optimistic, supported by the company’s rapid revenue growth and expanding product approvals in the US pharmaceutical market. The company’s strengths include a robust portfolio of specialty and generic formulations, strong R&D capabilities in India and Canada, and regulatory compliance with US FDA, WHO-GMP, and Health Canada standards. Rubicon has a competitive edge with 72 active ANDAs and 9 NDAs approved, positioning it as a significant player in regulated markets.
Risks encompass dependence on the US market, regulatory challenges, and volatility in R&D outcomes. The valuation analysis for financial year 2025 highlights Rubicon Research IPO with a Return on Equity (ROE) of 29.02%, Return on Capital Employed (ROCE) of 26.45%, and Net Asset Value (NAV) of ₹35.53, underscoring profitability and capital efficiency. Long-term investors may find potential in Rubicon’s strong market foothold and innovation pipeline.
Investor Considerations
Rubicon Research IPO demonstrates solid company performance with revenues rising 49% from ₹872.39 crore in FY 2024 to ₹1,296.22 crore in FY 2025 and a PAT margin of 10.37%, indicating healthy profitability. The pharmaceutical formulations sector outlook remains robust, driven by increasing demand in regulated markets, especially the US. The Rubicon Research IPO valuation for financial year 2025 shows a Return on Net Worth of 29.02%, EBITDA Margin of 20.67%, and Debt to Equity ratio of 0.51, reflecting strong financial health and moderate leverage.
Growth prospects are fueled by a rich pipeline of ANDAs and NDAs, regulatory approvals, and expanding US market presence. Risks include regulatory compliance, dependency on US markets, and R&D uncertainties. Long-term investors may benefit from Rubicon’s innovation-driven growth, while short-term investors should watch market/listing conditions closely.
| Date | GMP | Trend |
|---|---|---|
| 15 Oct 2025 19.26 | ₹155 | Up |
| 14 Oct 2025 11.51 | ₹130 | Up |
| 13 Oct 2025 20.00 | ₹120 | Up |
| 12 Oct 2025 17.30 | ₹110 | --- |
| 11 Oct 2025 11.16 | ₹110 | --- |
| 10 Oct 2025 13.33 | ₹110 | Up |
| 09 Oct 2025 11.01 | ₹100 | Up |
| 08 Oct 2025 10.49 | ₹80 | --- |
| 07 Oct 2025 13.15 | ₹80 | --- |
| 06 Oct 2025 19.39 | ₹80 | Up |
| 04 Oct 2025 11.25 | ₹00 | --- |
| 03 Oct 2025 19.26 | ₹00 | --- |
FAQs
The Grey Market Premium showed good accuracy in predicting Rubicon Research IPO’s listing performance. With a final GMP of ₹155, it projected a premium of 32.0% over the issue price of ₹485. The stock listed at ₹620.00, delivering a gain of 27.8%. This resulted in a moderate prediction error of 4.2%, where the GMP correctly signaled a positive listing and slightly overestimated the actual gain, reflecting strong reliability in this case.
Rubicon Research IPO Current GMP is ₹155.
Rubicon Research IPO Expected Returns is 31.96%.
Rubicon Research IPO estimated listing price is ₹640.